Edition:
United States

Resmed Inc (RMD)

RMD on New York Consolidated

77.00USD
21 Jul 2017
Change (% chg)

$-1.03 (-1.32%)
Prev Close
$78.03
Open
$78.04
Day's High
$78.24
Day's Low
$76.68
Volume
1,268,179
Avg. Vol
705,656
52-wk High
$79.44
52-wk Low
$56.59

RMD

Chart for RMD

About

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD),... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $10,920.08
Shares Outstanding(Mil.): 141.82
Dividend: 0.33
Yield (%): 1.71

Financials

  RMD Industry Sector
P/E (TTM): 32.82 38.17 15.85
EPS (TTM): 2.35 -- --
ROI: 12.73 8.73 -8.31
ROE: 18.92 13.52 -7.95

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 17 2017

BRIEF-Resmed plans to renew its patent infringement case against Fisher & Paykel

* Statement by ResMed on plans to renew its patent infringement case against Fisher & Paykel

May 17 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 16 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON, May 17 Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 16 2017

BRIEF-Resmed Q3 gaap earnings per share $0.62

* Resmed Inc. Announces results for the third quarter of fiscal year 2017

Apr 27 2017

BRIEF-ResMed provides data on patients with untreated sleep apnea

* New resmed-sponsored study shows promising treatment option for patients with untreated central sleep apnea Source text for Eikon: Further company coverage:

Apr 06 2017

BRIEF-ResMed reports Q2 earnings per share $0.54

* Announces results for the second quarter of fiscal year 2017

Jan 23 2017

Earnings vs. Estimates